Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation - PubMed (original) (raw)
. 2003 Jun 13;278(24):21732-43.
doi: 10.1074/jbc.M213247200. Epub 2003 Mar 26.
Affiliations
- PMID: 12663673
- DOI: 10.1074/jbc.M213247200
Free article
Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation
Bettina Drisaldi et al. J Biol Chem. 2003.
Free article
Abstract
The cellular mechanisms by which prions cause neurological dysfunction are poorly understood. To address this issue, we have been using cultured cells to analyze the localization, biosynthesis, and metabolism of PrP molecules carrying mutations associated with familial prion diseases. We report here that mutant PrP molecules are delayed in their maturation to an endoglycosidase H-resistant form after biosynthetic labeling, suggesting that they are impaired in their exit from the endoplasmic reticulum (ER). However, we find that proteasome inhibitors have no effect on the maturation or turnover of either mutant or wild-type PrP molecules. Thus, in contrast to recent studies from other laboratories, our work indicates that PrP is not subject to retrotranslocation from the ER into the cytoplasm prior to degradation by the proteasome. We find that in transfected cells, but not in cultured neurons, proteasome inhibitors cause accumulation of an unglycosylated, signal peptide-bearing form of PrP on the cytoplasmic face of the ER membrane. Thus, under conditions of elevated expression, a small fraction of PrP chains is not translocated into the ER lumen during synthesis, and is rapidly degraded in the cytoplasm by the proteasome. Finally, we report a previously unappreciated artifact caused by treatment of cells with proteasome inhibitors: an increase in PrP mRNA level and synthetic rate when the protein is expressed from a vector containing a viral promoter. We suggest that this phenomenon may explain some of the dramatic effects of proteasome inhibitors observed in other studies. Our results clarify the role of the proteasome in the cell biology of PrP, and suggest reasonable hypotheses for the molecular pathology of inherited prion diseases.
Similar articles
- A transmembrane form of the prion protein contains an uncleaved signal peptide and is retained in the endoplasmic Reticulum.
Stewart RS, Drisaldi B, Harris DA. Stewart RS, et al. Mol Biol Cell. 2001 Apr;12(4):881-9. doi: 10.1091/mbc.12.4.881. Mol Biol Cell. 2001. PMID: 11294893 Free PMC article. - Cytosolic prion protein (PrP) is not toxic in N2a cells and primary neurons expressing pathogenic PrP mutations.
Fioriti L, Dossena S, Stewart LR, Stewart RS, Harris DA, Forloni G, Chiesa R. Fioriti L, et al. J Biol Chem. 2005 Mar 25;280(12):11320-8. doi: 10.1074/jbc.M412441200. Epub 2005 Jan 4. J Biol Chem. 2005. PMID: 15632159 - Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein.
Yedidia Y, Horonchik L, Tzaban S, Yanai A, Taraboulos A. Yedidia Y, et al. EMBO J. 2001 Oct 1;20(19):5383-91. doi: 10.1093/emboj/20.19.5383. EMBO J. 2001. PMID: 11574470 Free PMC article. - Expression of mutant or cytosolic PrP in transgenic mice and cells is not associated with endoplasmic reticulum stress or proteasome dysfunction.
Quaglio E, Restelli E, Garofoli A, Dossena S, De Luigi A, Tagliavacca L, Imperiale D, Migheli A, Salmona M, Sitia R, Forloni G, Chiesa R. Quaglio E, et al. PLoS One. 2011 Apr 29;6(4):e19339. doi: 10.1371/journal.pone.0019339. PLoS One. 2011. PMID: 21559407 Free PMC article. - Intracellular distribution of proteasomes.
Rivett AJ. Rivett AJ. Curr Opin Immunol. 1998 Feb;10(1):110-4. doi: 10.1016/s0952-7915(98)80040-x. Curr Opin Immunol. 1998. PMID: 9523120 Review.
Cited by
- Activation of Src family kinase ameliorates secretory trafficking in mutant prion protein cells.
Restelli E, Capone V, Pozzoli M, Ortolan D, Quaglio E, Corbelli A, Fiordaliso F, Beznoussenko GV, Artuso V, Roiter I, Sallese M, Chiesa R. Restelli E, et al. J Biol Chem. 2021 Jan-Jun;296:100490. doi: 10.1016/j.jbc.2021.100490. Epub 2021 Mar 1. J Biol Chem. 2021. PMID: 33662396 Free PMC article. - Prion protein with an insertional mutation accumulates on axonal and dendritic plasmalemma and is associated with distinctive ultrastructural changes.
Jeffrey M, Goodsir C, McGovern G, Barmada SJ, Medrano AZ, Harris DA. Jeffrey M, et al. Am J Pathol. 2009 Sep;175(3):1208-17. doi: 10.2353/ajpath.2009.090125. Epub 2009 Aug 21. Am J Pathol. 2009. PMID: 19700753 Free PMC article. - The efficiency of protein compartmentalization into the secretory pathway.
Levine CG, Mitra D, Sharma A, Smith CL, Hegde RS. Levine CG, et al. Mol Biol Cell. 2005 Jan;16(1):279-91. doi: 10.1091/mbc.e04-06-0508. Epub 2004 Oct 20. Mol Biol Cell. 2005. PMID: 15496459 Free PMC article. - Functionally relevant domains of the prion protein identified in vivo.
Baumann F, Pahnke J, Radovanovic I, Rülicke T, Bremer J, Tolnay M, Aguzzi A. Baumann F, et al. PLoS One. 2009 Sep 7;4(9):e6707. doi: 10.1371/journal.pone.0006707. PLoS One. 2009. PMID: 19738901 Free PMC article. - An N-terminal polybasic domain and cell surface localization are required for mutant prion protein toxicity.
Solomon IH, Khatri N, Biasini E, Massignan T, Huettner JE, Harris DA. Solomon IH, et al. J Biol Chem. 2011 Apr 22;286(16):14724-36. doi: 10.1074/jbc.M110.214973. Epub 2011 Mar 8. J Biol Chem. 2011. PMID: 21385869 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials